A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Key Inclusion Criteria: * Male or female ≥2 years of age at the Screening visit. * Clinical diagnosis of RDEB with confirmation of COL7A1 genetic mutation. Key Exclusion Criteria: * Medical instability limiting ability to travel to the investigative site. * Active infection with human immunodeficiency virus, hepatitis B or hepatitis C. * The presence of COL7 antibodies. * Evidence of systemic infection. * Evidence or history of squamous cell carcinoma at the site to be injected. * Evidence of or history of metastatic squamous cell carcinoma. * Known allergy to any of the constituents of the product. * Female who is pregnant or breastfeeding. * Receipt of a chemical or biological intervention for the specific treatment of RDEB in the past three (3) months prior to screening or anticipated/planned during the screening and treatment period for this study.